Time in therapeutic range with vitamin K antagonists in congenital heart disease: a multicenter study.

[1]  M. Schwerzmann,et al.  2020 ESC Guidelines for themanagement of adult congenital heart disease , 2021, Russian Journal of Cardiology.

[2]  M. Schwerzmann,et al.  Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. , 2020, International journal of cardiology.

[3]  M. Schwerzmann,et al.  Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease. , 2019, The Canadian journal of cardiology.

[4]  Joseph D. Kay,et al.  Thromboembolic Risk After Atriopulmonary, Lateral Tunnel, and Extracardiac Conduit Fontan Surgery. , 2019, Journal of the American College of Cardiology.

[5]  M. Schwerzmann,et al.  Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe , 2019, Open Heart.

[6]  Stephanie Fuller,et al.  2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Circulation.

[7]  J. Berger,et al.  Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. , 2018, Journal of the American College of Cardiology.

[8]  P. Ermis,et al.  Novel oral anticoagulant use in adult Fontan patients: A single center experience , 2018, Congenital heart disease.

[9]  Joseph D. Kay,et al.  Increasing Prevalence of Atrial Fibrillation and Permanent Atrial Arrhythmias in Congenital Heart Disease. , 2017, Journal of the American College of Cardiology.

[10]  J. Reiffel.  Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum , 2017, The Journal of innovations in cardiac rhythm management.

[11]  Joseph D. Kay,et al.  Thromboprophylaxis for atrial arrhythmias in congenital heart disease: A multicenter study. , 2016, International journal of cardiology.

[12]  J. Galati,et al.  No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[13]  M. Mizuno,et al.  Prevalence and predictors of haemostatic complications in 412 Fontan patients: their relation to anticoagulation and haemodynamics. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  Bennett P. Samuel,et al.  Thrombosis in Fontan patient on apixaban. , 2015, International journal of cardiology.

[15]  L. Søndergaard,et al.  Anticoagulation in adults with congenital heart disease: The who, the when and the how? , 2014, Heart.

[16]  John K. Triedman,et al.  PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: Executive Summary , 2014 .

[17]  E. Hylek,et al.  National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation , 2014, Circulation.

[18]  P. Khairy.  Thrombosis in congenital heart disease , 2013, Expert review of cardiovascular therapy.

[19]  J. Mayer,et al.  Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. , 2013, International journal of cardiology.

[20]  B. McCrindle,et al.  Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. , 2013, Journal of the American College of Cardiology.

[21]  M. Rosenqvist,et al.  Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. , 2011, European heart journal.

[22]  B. McCrindle,et al.  A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. , 2011, Journal of the American College of Cardiology.

[23]  M. Schwerzmann,et al.  Cerebrovascular accidents in adult patients with congenital heart disease , 2010, Heart.

[24]  M. Schwerzmann,et al.  Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions. , 2010, The Canadian journal of cardiology.

[25]  S. Yusuf,et al.  Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range , 2008, Circulation.

[26]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[27]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[28]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[29]  D. Pennell,et al.  Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.

[30]  J. Speckman,et al.  Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range , 2003, Journal of Thrombosis and Thrombolysis.

[31]  S. Looney,et al.  Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms , 2002, Journal of Thrombosis and Thrombolysis.

[32]  V. Hjortdal,et al.  Self-management of oral anticoagulation in children with congenital heart disease , 2001, Cardiology in the Young.

[33]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.